Single-molecule observations of topotecan-mediated TopIB activity at a unique DNA sequence

Daniel A Koster1, Fabian Czerwinski, Ludovic Halby

  • 1Kavli Institute of Nanoscience, Faculty of Applied Sciences, Delft University of Technology, Lorentzweg 1, 2628 CJ Delft, The Netherlands.

Nucleic Acids Research
|February 23, 2008
PubMed

Insights

Camptothecin drugs slow DNA supercoil removal by human topoisomerase IB (TopIB). This study shows DNA sequence does not affect TopIB-drug interactions, simplifying future drug development.

Area of Science:

  • Molecular Biology
  • Biophysics
  • Pharmacology

Background:

  • Human topoisomerase IB (TopIB) is crucial for managing DNA topology.
  • Camptothecin drugs inhibit TopIB by trapping it in a covalent complex with DNA.
  • Understanding TopIB-drug interactions is key for developing new anticancer therapies.

Purpose of the Study:

  • To investigate the impact of DNA sequence on the dynamics of TopIB inhibition by camptothecins.
  • To quantify the effect of camptothecins on the rate of supercoil removal by TopIB at a specific DNA site.
  • To determine if sequence-specific interactions influence the lifetime of the TopIB-drug-DNA complex.

Main Methods:

  • Utilized single-molecule magnetic tweezers to monitor DNA supercoil removal in real time.
  • Covalently attached camptothecins to a triple helix-forming oligonucleotide for site-specific drug interaction.
  • Measured the rate of supercoil removal and covalent complex lifetime under controlled conditions.

Main Results:

  • The rate of DNA supercoil removal by drug-bound TopIB was independent of the specific DNA sequence.
  • Restricting camptothecin interaction to a single DNA site yielded dynamics indistinguishable from multi-site interactions.
  • Camptothecins' effect on the covalent complex lifetime was not sequence-dependent.

Conclusions:

  • DNA sequence does not influence the dynamics of TopIB inhibition by camptothecins.
  • The findings simplify the development of novel camptothecin-based anticancer drugs by removing sequence-dependency considerations.
  • This research provides a foundation for rational drug design targeting TopIB.